Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,710JPY
26 Mar 2019
Change (% chg)

¥111 (+2.41%)
Prev Close
¥4,599
Open
¥4,618
Day's High
¥4,723
Day's Low
¥4,604
Volume
8,626,300
Avg. Vol
11,195,843
52-wk High
¥5,645
52-wk Low
¥3,498

Latest Key Developments (Source: Significant Developments)

LegoChem Biosciences, Takeda Enter into Multi-Target Research Collaboration and License Agreement
Friday, 22 Mar 2019 

March 22 (Reuters) - LegoChem Biosciences Inc <141080.KQ>::LEGOCHEM BIOSCIENCES, TAKEDA ENTER INTO MULTI-TARGET RESEARCH AND LICENSE AGREEMENT FOR DEVELOPMENT OF ANTIBODY-DRUG CONJUGATES IN IMMUNO-ONCOLOGY.TAKEDA OBTAINS RIGHTS TO LCB'S ADC PLATFORM FOR MULTIPLE TARGETS.LCB WILL RECEIVE $7.25 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS..LCB ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONE PAYMENTS OF UP TO $404 MILLION.LCB ELIGIBLE TO RECEIVE ROYALTIES ON SALES OF ANY RESULTING ADC PRODUCTS.  Full Article

Takeda And Hemoshear Therapeutics Extend Exclusive Drug Discovery Partnership In Liver Diseases
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA AND HEMOSHEAR THERAPEUTICS EXTEND EXCLUSIVE DRUG DISCOVERY PARTNERSHIP IN LIVER DISEASES.HEMOSHEAR THERAPEUTICS- HEMOSHEAR WAS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF POTENTIALLY $470 MILLION AND ROYALTIES.HEMOSHEAR THERAPEUTICS- FURTHER ADDITIONAL FINANCIAL TERMS RELATED TO EXTENSION OF PARTNERSHIP WERE NOT DISCLOSED.  Full Article

Takeda Receives U.S. FDA Approval To Manufacture Flexbumin At New Plasma Manufacturing Facility
Monday, 18 Mar 2019 

March 18 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA RECEIVES U.S. FDA APPROVAL TO MANUFACTURE FLEXBUMIN® AT NEW PLASMA MANUFACTURING FACILITY NEAR COVINGTON, GEORGIA.TAKEDA PHARMACEUTICAL - FDA APPROVED SECOND SUBMISSION FOR ITS NEW PLASMA MANUFACTURING FACILITY FOR PRODUCTION OF FLEXBUMIN 25% USP, 25% SOLUTION.  Full Article

Infinity Pharmaceuticals Announces Royalty Monetization Of COPIKTRA For $30 Mln Gross Proceeds
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS ANNOUNCES ROYALTY MONETIZATION OF COPIKTRA FOR $30 MILLION GROSS PROCEEDS.INFINITY PHARMACEUTICALS INC - ANNOUNCED ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS (HCR) FOR RIGHT TO RECEIVE CERTAIN ROYALTY PAYMENTS.INFINITY PHARMACEUTICALS INC - ROYALTY PAYMENTS BASED ON WORLDWIDE ANNUAL NET SALES OF COPIKTRA (DUVELISIB), PAYABLE BY VERASTEM.INFINITY PHARMACEUTICALS - UNDER AGREEMENT, HCR HAS AGREED TO PAY CO A $30 MILLION UPFRONT PAYMENT AND UP TO $20 MILLION IN POTENTIAL MILESTONE PAYMENTS.INFINITY PHARMACEUTICALS INC - IN CONNECTION WITH ROYALTY MONETIZATION, INFINITY ENTERED INTO AN AMENDMENT OF ITS LICENSE AGREEMENT WITH TAKEDA.INFINITY PHARMACEUTICALS - AS PER AMENDMENT OF LICENSE AGREEMENT WITH TAKEDA, TAKEDA HAS AGREED TO RECEIVE A PORTION OF TOTAL INVESTMENT AMOUNT.  Full Article

Takeda's Global Acquisition Of Shire Creates An Expanded Takeda Canada
Thursday, 10 Jan 2019 

Jan 10 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA'S GLOBAL ACQUISITION OF SHIRE CREATES AN EXPANDED TAKEDA CANADA TO BRING BETTER HEALTH AND A BRIGHTER FUTURE TO CANADIANS.  Full Article

Shire Says Following Court Order, Scheme Has Now Become Effective
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Shire Plc::SHIRE PLC - FOLLOWING COURT ORDER , SCHEME HAS NOW BECOME EFFECTIVE, ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF SHIRE IS NOW OWNED BY TAKEDA.  Full Article

Takeda - Notice Regarding Amounts Of Capital And Capital Reserves To Be Increased By Issuance Of New Shares In Connection With Shire Acquisition
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::NOTICE REGARDING AMOUNTS OF CAPITAL AND CAPITAL RESERVES TO BE INCREASED BY ISSUANCE OF NEW SHARES IN CONNECTION WITH SHIRE ACQUISITION.AMOUNTS OF BOTH STATED CAPITAL AND CAPITAL RESERVES TO BE INCREASED BY ABOUT 1.565 TRLN YEN EACH.  Full Article

Takeda Says It Now Owns Entire Issued And To Be Issued Share Capital Of Shire
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T>::NOTICE REGARDING THE ACQUISITION OF THE ENTIRE ISSUED AND TO BE ISSUED SHARE OF SHIRE.CONFIRMS SCHEME OF ARRANGEMENT IN RELATION TO PROPOSED ACQUISITION OF SHIRE BECAME EFFECTIVE JAN 8.ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF SHIRE IS NOW OWNED BY TAKEDA.  Full Article

Shire Plc Says Thomas Dittrich, Chief Financial Officer And Executive Director, Has Resigned
Tuesday, 8 Jan 2019 

Jan 7 (Reuters) - Shire Plc ::SAYS THOMAS DITTRICH, CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR, HAS RESIGNED.ANNOUNCES THAT DIRECTORS OF SHIRE HAVE TENDERED THEIR RESIGNATIONS.SHIRE-FLEMMING ORNSKOV WILL BE RETAINED BY SHIRE AS EMPLOYEE TO ACT IN AN ADVISORY CAPACITY TO CEO OF TAKEDA FOR THREE MONTHS ENDING ON MARCH 31, 2019.FLEMMING ORNSKOV, CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR, HAS RESIGNED.SHIRE - THOMAS DITTRICH WILL BE RETAINED BY SHIRE AS AN EMPLOYEE TO ACT IN ADVISORY CAPACITY TO CHIEF FINANCIAL OFFICER OF TAKEDA UNTIL MARCH 3, 2019.TAKEDA HAS APPOINTED OLIVIER BOHUON, IAN CLARK AND STEVEN GILLIS TO THE TAKEDA BOARD EFFECTIVE AS OF TODAY’S DATE.AMONG DIRECTORS OF SHIRE TO HAVE TENDERED RESIGNATION IS SUSAN KILSBY, NON-EXECUTIVE DIRECTOR AND CHAIRMAN.  Full Article

Takeda CEO Says Selling Consumer Business Is Not Our First Priority In Terms Of Accelerating Deleverage
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Takeda <4502.T>::CEO SAYS SELLING CONSUMER BUSINESS IS NOT OUR FIRST PRIORITY IN TERMS OF ACCELERATING DELEVERAGE.  Full Article